US pharmaceutical company Merck & Co Inc (NYSE:MRK) has signed eight deals to sell in total more than two million courses of its experimental COVID-19 pill, molnupiravir, to governments around the world, Reuters news agency reported on Wednesday.
This pill is developed by Merck and Ridgeback Biotherapeutics LP.
Countries Merck has signed the deals with include Australia for 300,000 doses, France for 50,000 doses, Indonesia, Malaysia for 150,000 courses, Philippines for 300,000 courses, Singapore , South Korea for 20,000 courses, Thailand for 200,000 courses and the US for 1,700,000 doses.
Merck has applied for approval in the United States and has said it can make 10 million courses in 2021.
Also, last week the company reached a deal with the United Nations-backed Medicines Patent Pool that will allow more companies to manufacture generic versions of the pill with a royalty-free license applying to 105 low- and middle-income countries.
So far, Merck has agreed to license the drug to several India-based generic drugmakers.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling